High Frequency of Fetal Loss in Fetuses With Normal Karyotype and Nuchal Translucency ≥ 3 Among the Iranian Pregnant Women

  • Shokoh Abotorabi Department of Obstetrics and Gynecology, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran
  • Niloufar Moeini Department of Biology, School of Basic Science, Qom Islamic Azad University, Qom, Iran
  • Sahar Moghbelinejad Mail Cellular and Molecular Research Centre, Qazvin University of Medical Sciences, Qazvin, Iran AND Khatam Pathobiology and Genetic Lab, Qazvin, Iran
Free-Beta Human Gonadotropin, Pregnancy Associated Protein-A, Nuchal Translucency, Pregnancy


Objective: The purpose of this study was comparison of association of three main first trimester screening factors with pregnancy outcomes among Iranian pregnant women.

Materials and methods: This prospective study was done during 2017-2019 years in Qazvin, Iran. To do so, a total of 1500pregnant women in first trimester were enrolled. At the first step, Nuchal translucency (NT) was measured in 11-13 ± 5 week, then the serum pregnancy-associated plasma protein A (PAPP-A) and free-β-human chorionic gonadotropin (free-β-HCG) were measured in 12-14 weeks of gestation. Pregnant women were followed up until the end of pregnancy for the complications of pregnancy such as intra-uterine growth retardation (IUGR), intrauterine death (IUFD), different types of fetal loss and preterm labor.
Results: The results showed that low levels of serum biomarkers had more association with pregnancy complications in comparison to high levels of them. Significant association of IUGR (P = 0.001), IUFD (P = 0.032) and pre-term labor (P = 0.002) was shown in women with low serum levels of PAPP-A in comparison to low serum levels of free-β-hCG. Significant high frequency of different types of fetal loss (IUFD, Abortion, Elective termination) was shown in fetuses with N ≥ 3 in comparison to low levels of serum biomarkers (P = 0.001). Conclusion: This study highlighted the importance of accurately interpreting the results of the first trimester of pregnancy screening which should be considered by primatologists for subsequent pregnancy care.


1. Goetzl L, Krantz D, Simpson JL, Silver RK, Zachary JM, Pergament E, et al. Pregnancy-associated plasma protein A, free β-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004; 104:30-6.
2. Schuchter K, Hafner E, Stangl G, Metzenbauer M, Ho finger D, Philipp K. The first trimester ‘combined test’ for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 2002; 22: 211–15.
3. Lawrence JB, Oxvig C, Overgaard MT, Sottrup –jensen L,GleicGJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA. 1999; 96: 3149-53.
4. Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv Clin Chem 2014; 63:169-209.
5. Smith GC, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 2006; 107: 161-6.
6. Tonskaker T, Bartlett G,Trpkow C. Health information on the Internet. Gold mine or minefield? Can FAM Physician 2014; 60: 407-8.
7. Butler SA, Iles RK. The free monomeric beta subunit of human chorionic gonadotrophin (hCG beta) and the recently identified homodimeric beta–beta subunit (hCG beta beta) both have autocrine growth effects. Tumour Biol 2004; 25:18–23.
8. Ulf-Hakan S, Aila T, Henrik A, Leena V. The classification, functions and clinical use of different isoforms of hCG. Hum Reprod Update 2006; 12: 769-84.
9. Cruz J, Cruz G, Minerkawa R, Mazi N, Nicolaides KH. Effect of temperature on free b-human chorionic gonadotropin and pregnancy-associated plasma protein-A concentration. Ultrasound Obstet Gynecol 2010; 36: 141–6.
10. Bogers H, Rifouna MS, Cohen-Overbeek TE, Koning AHJ, Willemsen SP, van der Spek PJ,et al. First trimester physiological development of the fetal foot position using three-dimensional ultrasound in virtual reality. J Obstet Gynaecol Res 2019; 45: 280-8.
11. Liu SS, Lee FK, Lee JL, Tsai MS, Cheng ML, She BQ, Chen SC. Pregnancy outcomes in unselected singleton pregnant women with an increased risk of first-trimester Down's syndrome. Acta Obstet Gynecol Scand 2004; 83: 1130–4.
12. Rozenberg P, Bussières L, Chevret S, Bernard JP, Malagrida L, Cuckle H, et al. Screening for Down syndrome using firsttrimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 2006; 195: 1379–87.
13. Snijders RJ, Noble P, Sebire N, Souka A, Nicolades KH. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10 – 14 weeks of gestation. Lancet 1998; 352: 343-6.
14. Rocha ADS, Bernardi JR, Matos S, Kretzer DC, Schöffel AC, Goldani MZ, et al.Maternal visceral adipose tissue during the first half of pregnancy predicts gestational diabetes at the time of delivery - a cohort study. PLoS One 2020; 15: e0232155.
15. Cuckle H, Arbuzova S, Spencer K, Crossley J, Barkai G, Krantz D, et al . Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. Prenat Diagn 2003; 23: 385-8.
16. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 2004; 131:1187-94.
17. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149-53.
18. Huynh L, Kingdom J, Akhtar S. Low pregnancy-associated plasma protein A level in the first trimester. Can Fam Physician 2014; 60:899-903.
19. 19.Saruhan Z, Ozakinci M, Simsek M, Mendilcioglu I. Association of first trimester low PAPP-A with adverse pregnancy outcomes. Clin Exp Obstet Gynecol 2012; 39: 225-8.
20. Shah KH, Anjum A, Nair P, Bhat P, Bhat RG, Bhat S. Pregnancy associated plasma protein A: An indicator of adverse obstetric outcomes in a South India population. Turk J Obstet Gynecol 2020; 17: 40-5.
21. Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn 2003; 23: 990-6.
22. Mendoza M, Garcia-Manau P, Arévalo S, Avilés M, Serrano B, Sánchez-Durán MÁ.Diagnostic accuracy of first-trimester combined screening for early-onset and preterm preeclampsia at 8-10 weeks compared to 11-13 weeks gestation.Ultrasound Obstet Gynecol 2020.
23. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab2002; 87: 1762-7.
24. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004; 191: 1446-51.
25. Kaijomaa M, Rahkonen L, Ulander VM, Hämäläinen E, Alfthan H, Markkanen H, et al. Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes. Int J Gynaecol Obstet 2017; 136: 76-82.
26. Lithner CU, Kublickas M, Ek S. Pregnancy outcome for fetuses with increased nuchal translucency but normal karyotype. J Med Screen 2016; 23:1-6.
27. Westin M, Saltvedt S, Bergman G, Almstrom H, Grunewlad C, Valentin L. Is measurement of nuchal translucency thickness a useful screening tool for heart defects? A study of 16,383 fetuses. Ultrasound Obstet Gynecol 2006; 27: 632–9.
28. Müller MA, Bleker OP, Bonsel GJ, Bilardo CM. Nuchal translucency screening and anxiety levels in pregnancy and puerperium. Ultrasound Obstet Gynecol 2006; 27: 357-61.
29. Vogel M, Sharland GK, McElhinney DB,Zidere V,Simpson JM,Miller OI, et al. Prevalence of increased nuchal translucency in fetuses with congenital cardiac disease and a normal karyotype. Cardiol Young 2009; 19: 441-5.
30. Clur SA, Ottenkamp J, Bilardo CM. The nuchal translucency and the fetal heart: a literature review. Prenat Diagn 2009; 29: 739-48.
31. De Domenico R, Faraci M, Hyseni E, Di Prima FA, Valenti O, Monte S, et al. Increased nuchal traslucency in normal karyotype fetuses. J Prenat Med 2011; 5: 23–6.
How to Cite
Abotorabi S, Moeini N, Moghbelinejad S. High Frequency of Fetal Loss in Fetuses With Normal Karyotype and Nuchal Translucency ≥ 3 Among the Iranian Pregnant Women. J Fam Reprod Health. 14(2):81-87.
Original Articles